Correlation of Timing of Pegfilgrastim Administration and the Improvement of PIBP and PRO.
PegfilgrastimBone Pain3 morePegfilgrastim induced-bone pain is a common and important clinical problem. Currently, there is no effective solution. The bone pain it causes usually begins on the day of pegfilgrastim administration. Chemotherapy can also cause pain, which typically begins 24 to 48 hours after the completion of chemotherapy and lasts for 3 to 5 days. Regarding the timing of pegfilgrastim administration, the NCCN (National Comprehensive Cancer Network) guidelines suggest that 2 to 4 days after completing the chemotherapy is reasonable. In contrast, pegfilgrastim often be administrated 24 to 48 hours after finishing the chemotherapy in current clinical practice. Bone pain may be alleviated by delaying pegfilgrastim administration until 72 hours after the completion of chemotherapy to reduce the superimposed pain caused by chemotherapy and Pegfilgrastim.
Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast...
HER2-positive Breast CancerThis Non-Interventional Study will describe and analyze the clinical use of pyrotinib in clinical practice in the treatment of HER2 positive breast cancer in the real world.
Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative...
Metastatic Triple-Negative Breast CarcinomaEvaluating the combination of the investigational, multi-peptide cancer vaccine PVX-410 in combination with pembrolizumab and chemotherapy in treatment naive patients with metastatic, triple negative breast cancer who are PDL1 and HLA A2 positive.
Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple...
Triple Negative Breast CancerThe INSTIGO study aims to assess a plasma protein profile at different stages of patient follow-up as a predictive factor of metastatic recurrence in triple negative breast cancer. It also aims to look at other potential biomarkers of metastatic relapse such as Tumor-infiltrating Lymphocytes, circulating tumor DNA, figurative elements in blood, or a tumor RNA signature.
Early Detection of CMP in Patients With Breast Cancer Using Cardiac Magnetic Resonance
Breast CancerChemotherapy Induced Systolic DysfunctionBreast cancer is the most common cancers among women worldwide.Although chemotherapy and surgery have greatly improved the survival rate, most types of chemotherapy have been reported to have varying degrees of cardiotoxicity. The investigators will focus on the cardiotoxicity of pyrotinib and apatinib which belong to the new tyrosine kinase inhibitors in respective chemotherapy among more subjects.
Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive...
Breast CancerNeoadjuvant Therapy1 moreToday, the majority of clinically node positive (cN+) breast cancer patients is treated with neoadjuvant systemic therapy (NST). Axillary staging and treatment after NST in cN+ patients are areas of controversy. Patients with a pathological complete response (pCR) of the axillary lymph nodes are not expected to benefit from axillary lymph node dissection (ALND). Hence, less invasive axillary staging procedures are being introduced to avoid unnecessary ALND. However, evidence supporting the safety of replacing ALND by less invasive techniques in terms of oncologic safety and impact on quality of life (QoL) is lacking.
Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+...
HER2+ Early or Locally Advanced Breast CancerThe study is being conducted to evaluate the efficacy, and safety of pyrotinib versus pertuzumab in combination with trastuzumab and nab-paclitaxel for neoadjuvant treatment in HER2+ early or locally advanced breast cancer patients. To explore whether pyrotinib regimen could provide better clinical results compared with pertuzumab in the study population.
Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
Breast CarcinomaBreast NeoplasmThis study evaluates the effectiveness of a breast ultrasound method for the diagnosis of breast cancer. Diagnostic procedures, such as breast ultrasound, may help find and diagnose breast cancer, and may help measure a patient's response to earlier treatment. The purpose of this research is to test the effectiveness of a new investigational breast ultrasound method to detect an abnormality in the breast, and assess response to breast cancer treatment.
Prospective Study of MAstectomy With Reconstruction Including Robot Endoscopic Surgery
Breast NeoplasmsGermline BRCA1 Gene Mutation3 moreRobotic mastectomy and immediate reconstruction have been introduced in 2015. However, since robotic mastectomy is the latest surgical technique, there is a lack of studies prospectively comparing conventional mastectomy and immediate reconstruction with robotic mastectomy. For this reason, this study is designed to establish a single institution cohort study that prospectively collects patients undergoing mastectomy and reconstruction. This study was initially designed as a single institution study, however, currently, the study was extended to the multicenter study including 22 institutions over the country. Using the established prospective cohort data, a comparative study of robotic mastectomy with conventional mastectomy and reconstruction, and cost-effectiveness and satisfaction of robotic endoscopic surgery, and cost-effectiveness and satisfaction of reconstructive surgery are to be analyzed.
Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone...
Web-applicationBreast Cancer1 moreThe investigators hypothesize that the implementation of a Web-application in patients initiating adjuvant hormone therapy for breast cancer brings a benefit on treatment adherence and quality of life.